Trial Search Results

Study of Blood Samples From Newborns With Down Syndrome

This research study is looking at blood samples from newborns with Down syndrome. Studying the genes expressed in samples of blood from patients with Down syndrome may help doctors identify biomarkers related to cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Children's Oncology Group

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Other: Diagnostic Laboratory Biomarker Analysis
  • Other: Pharmacological Study

Eligibility


Inclusion Criteria:

   - Diagnosis of transient myeloproliferative disorder (TMD) at < 90 days of age and
   meeting 1 of the following criteria:

      - A diagnosis of Down syndrome or Down syndrome mosaicism AND non-erythroid and
      non-lymphoid blasts (any amount) in the peripheral blood verified with a second
      sample

         - Patients with typical physical characteristics of Down syndrome are allowed
         before cytogenetic or FISH confirmation of the diagnosis

      - Trisomy 21-positive leukemic blasts documented by biopsy of any organ (including
      > 5% non-erythroid/non-lymphoid blasts documented by bone marrow aspirate or
      biopsy)

         - Infants with isolated trisomy 21 positivity identified only in the leukemic
         blasts are allowed

   - Institutional immunophenotype characterization is required for study enrollment

Ages Eligible for Study

N/A - 90 Days

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting